Ramucirumab Biosimilar - Research Grade

Human

VEGFR2

>1mg/ml

Human IgG1

Humanized

Anti-Mouse CD309 (DC101) In Vivo Antibody - Low Endotoxin (ICH1232), Olinvacimab Biosimilar - Research Grade (ICH5729), Pulocimab Biosimilar - Research Grade (ICH5792), Vulinacimab Biosimilar - Research Grade (ICH5994)

https://www.imgt.org/mAb-DB/

ICH3001-100ml ICH3002-100ml ICH3003-100ml

P35968

3791

RRID:AB_2921547

Blue ice

This is a research-grade, unconjugated non-therapeutic recombinant analog of ramucirumab, a fully human IgG1 antibody directed against the extracellular domain of human VEGFR2 (KDR, UniProt P35968). It is built to reproduce the binding specificity of the originator molecule so researchers can study VEGFR2 blockade in defined experimental systems, while remaining strictly for research use only and not for human or veterinary use. Supplied unconjugated, it is well suited as a positive control or reference reagent in ligand-blocking and receptor-binding assays, as a benchmarking tool against other anti-VEGFR2 binders, and as a starting point for ADC or bispecific development workflows. The material is offered at research and ultra-low endotoxin grades (typically <1 EU/mg, with <0.5 EU/mg options) and in bulk milligram-to-gram quantities, supporting reproducible in-vitro work and larger preclinical study designs where lot consistency and low endotoxin burden matter. It is a target-directed analog and is not the clinical product. VEGFR2 (KDR/Flk-1; UniProt P35968) is a receptor tyrosine kinase and the principal signaling receptor for vascular endothelial growth factor A (VEGF-A), and it also binds VEGF-C and VEGF-D. It is expressed predominantly on vascular and lymphatic endothelial cells. Ligand engagement drives receptor dimerization, autophosphorylation of intracellular tyrosine residues, and activation of downstream pathways including PLCgamma-PKC-MAPK, PI3K-AKT, and pathways governing endothelial proliferation, migration, survival, and vascular permeability. Through these outputs VEGFR2 is a central driver of physiological and pathological angiogenesis and lymphangiogenesis. Because tumor neovascularization depends heavily on VEGF-A/VEGFR2 signaling, the receptor is a validated oncology and vascular-biology target, and antibodies that block the ligand-binding extracellular domain interrupt this axis at the receptor level.

Vascular endothelial growth factor receptor 2, Kdr, VEGFR-2, Fetal liver kinase 1, FLK-1, Kinase NYK, Protein-tyrosine kinase receptor flk-1, Flk1, CD309

Detects human VEGFR2. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Ramucirumab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Phosphate buffered saline (PBS) pH 7.2,with no carrier protein, potassium or preservatives added. BSA and Azide free.

Stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

SIM0012

Ramucirumab (anti-VEGFR2) Biosimilar

Q: Is the Ramucirumab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Ramucirumab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Ramucirumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Ramucirumab that binds human VEGFR2.